IDEAYA Biosciences Announces Promising Phase 1 Clinical Trial Results for IDE849 in SCLC and Other DLL3 Upregulated Tumors at WCLC 2025
I'm PortAI, I can summarize articles.
IDEAYA Biosciences, in collaboration with Hengrui Pharma, announced promising Phase 1 clinical trial results for IDE849, a DLL3-targeting antibody drug conjugate, at the IASLC 2025 World Conference on Lung Cancer. The trial involved 100 patients and showed a manageable safety profile with a median progression-free survival of 6.7 months at doses of 2.4 mg/kg or higher. Further updates will be available on IDEAYA’s Investor Relations page.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments